You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
天士力(600535.SH):右佐匹克隆片獲仿製藥一致性評價
格隆匯 10-22 15:55

格隆匯10月22日丨天士力(600535.SH)公佈,近日,公司全資子公司江蘇天士力帝益藥業有限公司(以下簡稱“江蘇帝益”)收到國家藥品監督管理局頒發的關於右佐匹克隆片(商品名“文飛”,以下簡稱“文飛”)3mg規格的《藥品補充批件》(批件號:2019B03973),該藥品通過仿製藥一致性評價。

文飛(右佐匹克隆片)是新一代非苯二氮卓類鎮靜催眠藥。對γ-氨基丁酸受體具有高選擇性,同時具有達峯時間1h,半衰期6h的藥代動力學特點,能夠快速吸收起效誘導睡眠,持續作用7-8h維持完整睡眠並且次晨後遺作用輕微的優點。2012年被收錄入《中國成人失眠診斷與治療指南》成為失眠治療一線治療藥物,並先後進入《中國失眠症診斷與治療指南》、《心血管疾病合併失眠診療中國專家共識》、《成人阻塞性睡眠呼吸暫停多學科診療指南》、《認知功能損害患者睡眠障礙評估和管理的專家共識》等多項指南與專家共識,在眾多失眠共病疾病領域獲得臨牀治療推薦。右佐匹克隆已進入國家醫保目錄。

目前於中國境內已上市的右佐匹克隆片包括上海上藥中西製藥有限公司的奧佑靜?(3mg)和成都康弘藥業集團股份有限公司的伊坦寧?(3mg)等。根據IQVIACHPA最新數據,右佐匹克隆2018年度國內樣本醫院用藥銷售額為2.09億人民,較2017年同期增加29.5%。

截至公告日,江蘇帝益針對該藥品一致性評價已投入研發費用約719.72萬元人民幣。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account